Fresenius Medical Care AG reports developments in kidney care, dialysis services, and dialysis products for individuals with renal disease. Company news commonly covers Care Delivery clinic operations, Care Enablement products such as dialysis machines, dialyzers, and the 5008X CAREsystem, and Value-Based Care activity, along with organic revenue, operating income, margins, leverage, and share buyback updates.
Other recurring items include portfolio optimization, research in hemodiafiltration, artificial intelligence and digital tools for nephrology, and governance changes affecting the Management Board and Supervisory Board. Updates also describe the company's Frankfurt and New York listings and shareholder matters tied to its ordinary shares and ADRs.
Fresenius Medical Care (FMS) narrowed its full-year operating income outlook after third-quarter earnings declined amid regulatory headwinds and higher costs. The company now expects 2026 revenue to be broadly flat and operating income growth between flat and a negative mid-single digit percentage.
Third-quarter revenue rose 1% to EUR 4,937 million, while reported operating income fell 19% to EUR 384 million. Net income attributable to shareholders declined 42% to EUR 160 million. China business changes generated EUR 108 million in one-time costs. Excluding special items, operating income fell 5% to EUR 545 million and basic earnings per share remained flat at EUR 1.11.
Operating cash flow increased 8% to EUR 798 million. The 5008X rollout reached approximately 16% of dialysis machines in U.S. clinics, on track for the company's full-year target of around 20%.
Fresenius Medical Care (FMS) launched its multiFiltratePRO System in the United States for critically ill patients with acute kidney injury. On October 19, 2026, the FDA cleared the system and approved its dedicated Cienby sodium citrate and Calrezdy calcium chloride solutions. The package supports regional citrate anticoagulation, which prevents clotting in the external blood circuit during continuous kidney replacement therapy.
The system is indicated for patients weighing 40 kilograms or more with acute renal failure, with or without fluid overload. Integrated citrate and calcium pumps automatically adjust infusion rates as treatment conditions change. The company plans a controlled U.S. rollout followed quickly by full availability.
Fresenius Medical Care (FMS) is presenting kidney-care research at ASN Kidney Week, taking place October 21–25, 2026, in Denver.
A U.S. study covering more than 10,000 treatments found that 74% achieved the high-volume hemodiafiltration target of at least 23 liters of convective volume. An analysis of approximately 5,000 dialysis patients associated GLP-1 receptor agonist use with lower mortality and fewer hospitalizations. A multicenter U.S. study of continuous renal replacement therapy in critically ill patients reported maintained anticoagulation targets, infrequent, manageable electrolyte disturbances and no observed citrate toxicity.
Fresenius Medical Care (FMS) appointed Shervin J. Korangy as CEO and Management Board Chair, effective October 12, 2026, succeeding Helen Giza. The Supervisory Board approved the appointment unanimously. Giza served four years as CEO after three years as CFO. During her leadership, portfolio optimization and the FME25+ transformation program streamlined operations and reduced the cost base by around EUR 1.2 billion.
The company said the transformation has largely achieved its objectives and the next growth phase calls for a different leadership profile. Korangy, formerly CEO of BVI Medical and a Supervisory Board member since 2023, plans to accelerate innovation, expand access to care and pursue long-term profitable growth. He has resigned his Supervisory Board seat; Ann Custin has been identified as his successor.
Fresenius Medical Care (FMS) announced on September 25, 2026, that it will exit its China peritoneal dialysis business and narrow its local portfolio.
It will discontinue local production and sales of the 4008A hemodialysis system while maintaining existing obligations in China. The company will focus on in-center dialysis and critical-care technologies, including the 5008S CAREsystem and multiFiltratePRO. It expects approximately €110 million in related one-time costs, primarily from impairments, scrappage and terminations, to be recognized as a special item in the third quarter of 2026. China accounts for approximately 6-7% of Care Enablement segment revenue. The company does not expect the portfolio changes to meaningfully affect that segment's future China revenue outlook.
Fresenius Medical Care (NYSE:FMS) announced publication in the Journal of the American Society of Nephrology of a large multinational real-world evidence study comparing hemodiafiltration (HDF) with conventional high-flux hemodialysis.
In nearly 20,000 patients across eight European countries, HDF was associated with a 28% lower relative risk of all-cause mortality. High-volume HDF (HVHDF), defined by sustained convection volumes above 23 liters per session, was associated with a 33% lower relative risk of death. The analysis used a target trial emulation design with advanced statistical methods and aligns with prior evidence, including the EU-funded CONVINCE trial, reinforcing HVHDF’s role in modern dialysis care.
Fresenius Medical Care (FMS) reported Q2 2026 revenue of EUR 4,861 million, up 1% year-on-year (+5% organic) with growth in all operating segments. Operating income rose 10% to EUR 466 million, while operating income excluding special items increased 20% to EUR 569 million, expanding the margin2 to 11.7%.
Net income declined 3% to EUR 218 million, but net income excluding special items grew 13% to EUR 303 million. Basic EPS increased 6% to EUR 0.81, and EPS excluding special items rose 24% to EUR 1.13, supported by share buybacks. Operating cash flow grew 11% to EUR 860 million; free cash flow was stable at EUR 625 million.
The FME25+ program delivered EUR 67 million additional sustainable savings in Q2, with around 100 U.S. clinics exited and related EUR 42 million special costs. The company cancelled 24.8 million shares (8.5% of capital) and began a second buyback of about EUR 1 billion. Fresenius Medical Care reaffirmed its 2026 outlook for broadly flat revenue and operating income2 within a mid-single digit range at constant currency, excluding special items.
Fresenius Medical Care (NYSE:FMS) announced that its Supervisory Board has appointed Cassie McLean (48) to the Management Board as Chief Executive Officer of the Care Delivery operating segment, effective 1 August 2026. She succeeds Craig Cordola (54), the prior CEO of Care Delivery.
McLean, who joined the company in August 2025 as President, Fresenius Kidney Care, will assume direct accountability for the global clinic business, including Fresenius Kidney Care in the U.S. and Care Delivery International. She previously served as CEO of Monte Nido and spent nearly 16 years at DaVita Kidney Care.
Fresenius Medical Care (NYSE:FMS) announced BEACON-US, a U.S. research initiative evaluating clinical outcomes and patient experience with high-volume hemodiafiltration (HVHDF) in routine dialysis practice. The program supports the company’s nationwide roll-out of online-HDF and its FME Reignite growth and innovation strategy.
According to Fresenius Medical Care, early U.S. observations show 40% fewer muscle cramps and more than 70% of treatments using AutoSub plus technology reaching the HVHDF target of at least 23 liters convective volume per session. International evidence, including the EU-funded CONVINCE trial, has associated HVHDF with fewer hospitalizations and a 23% lower risk of death versus conventional high-flux hemodialysis.
Fresenius Medical Care (NYSE:FMS) introduced TherapyWise, a cloud-based analytics capability integrated into NxView 4.0, the FDA 510(k)-cleared software platform used with the NxStage System One for kidney replacement therapy in U.S. acute and critical care settings.
TherapyWise aggregates retrospective program-level data from ICU kidney replacement therapy, summarizing metrics such as average delivered versus set dose, treatment time per cartridge, and alarm frequency trends. It is designed for oversight and quality improvement, not real-time patient-specific decision-making, which remains the responsibility of attending clinicians.